Hester Biosciences Ltd
Hester Biosciences Ltd (HESTERBIO) last reported results for the quarter ended Jun 2026, with sales of ₹77 crore and net profit of ₹97 crore. The stock last traded at ₹2,123, a market capitalisation of ₹1,806 crore, on a P/E of 34.0. Over the past 52 weeks the stock has ranged between ₹1,239 and ₹2,684. Figures are as of 6 Oct 2026 and are not real time.
Hester Biosciences Ltd share price and key metrics
- Current price
- ₹2,123
- Market cap
- ₹1,806 cr
- Stock P/E
- 34.0
- Book value
- ₹423
- ROE
- 15.9%
- ROCE
- 15.2%
- Dividend yield
- 0.51%
- 52w high / low
- 2684/1239
Metrics as of 6 Oct 2026. Not real time.
Track Hester Biosciences Ltd
Cruxal reads every Hester Biosciences Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Hester Biosciences Ltd growth and returns
- 10 Years
- 13%
- 5 Years
- 9%
- 3 Years
- 8%
- TTM
- 4%
- 10 Years
- 11%
- 5 Years
- 8%
- 3 Years
- 26%
- TTM
- 41%
- 10 Years
- 11%
- 5 Years
- -3%
- 3 Years
- 7%
- 1 Year
- 17%
- 10 Years
- 14%
- 5 Years
- 12%
- 3 Years
- 11%
- Last Year
- 16%
Hester Biosciences Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹77 cr, down 8.3% from ₹84 cr a year earlier. Net profit was ₹97 cr, up 470.6% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 84 | 63 | 82 | 84 | 71 | 77 | 100 | 77 |
| Expenses | 65 | 58 | 63 | 61 | 59 | 60 | 66 | 54 |
| Operating profit | 19 | 5 | 19 | 23 | 12 | 18 | 34 | 23 |
| OPM % | 23% | 8% | 23% | 27% | 17% | 23% | 34% | 29% |
| Other income | 3 | 9 | -6 | 3 | 12 | 2 | 2 | 89 |
| Interest | 6 | -4 | 6 | 2 | 2 | 2 | 5 | 3 |
| Depreciation | 4 | 4 | 4 | 4 | 4 | 4 | 6 | 7 |
| Profit before tax | 12 | 13 | 4 | 20 | 17 | 14 | 25 | 102 |
| Tax % | 29% | 15% | 59% | 14% | 16% | 31% | 34% | 5% |
| Net profit | 8 | 11 | 2 | 17 | 14 | 9 | 17 | 97 |
| EPS (₹) | 9.64 | 13.71 | 1.52 | 19.33 | 16.99 | 10.31 | 18.78 | 114.00 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Hester Biosciences Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 123 | 136 | 178 | 183 | 214 | 235 | 266 | 305 | 311 | 333 | 326 |
| Operating profit | 41 | 47 | 68 | 55 | 69 | 60 | 51 | 54 | 62 | 87 | 87 |
| OPM % | 33% | 35% | 38% | 30% | 32% | 26% | 19% | 18% | 20% | 26% | 27% |
| Net profit | 23 | 23 | 41 | 31 | 35 | 39 | 28 | 21 | 29 | 57 | 137 |
| EPS (₹) | 27.68 | 30.12 | 48.87 | 34.29 | 40.47 | 46.22 | 31.30 | 22.21 | 32.31 | 65.41 | 160.08 |
TTM is the trailing twelve months to the most recent quarter.
Hester Biosciences Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 |
| Reserves | 113 | 132 | 169 | 193 | 220 | 251 | 271 | 283 | 306 | 352 |
| Borrowings | 66 | 69 | 90 | 121 | 105 | 228 | 274 | 244 | 213 | 195 |
| Other liabilities | 25 | 35 | 32 | 65 | 78 | 74 | 116 | 126 | 126 | 123 |
| Total liabilities | 213 | 244 | 299 | 387 | 411 | 562 | 670 | 662 | 653 | 678 |
| Fixed assets | 102 | 110 | 145 | 143 | 133 | 237 | 259 | 240 | 233 | 411 |
| CWIP | 21 | 32 | 7 | 74 | 109 | 82 | 149 | 171 | 183 | 9 |
| Investments | 0 | 0 | 0 | 0 | 0 | 21 | 25 | 30 | 34 | 43 |
| Other assets | 89 | 102 | 148 | 170 | 169 | 222 | 237 | 221 | 203 | 215 |
| Total assets | 213 | 244 | 299 | 387 | 411 | 562 | 670 | 662 | 653 | 678 |
As reported by the company. Total assets equal total liabilities by construction.
Hester Biosciences Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 35 | 38 | 47 | 37 | 58 | 9 | 24 | 48 | 65 | 64 |
| Cash from investing | -30 | -26 | -21 | -73 | -42 | -117 | -77 | -22 | -20 | -18 |
| Cash from financing | 2 | -11 | 3 | 19 | -18 | 112 | 42 | -26 | -52 | -49 |
| Net cash flow | 6 | 1 | 28 | -17 | -2 | 3 | -12 | -0 | -7 | -3 |
| Free cash flow | 5 | 15 | 24 | -36 | 17 | -87 | -54 | 24 | 44 | 47 |
| CFO / operating profit | 102% | 100% | 92% | 86% | 105% | 43% | 63% | 112% | 123% | 90% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Hester Biosciences Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 19% | 20% | 26% | 16% | 18% | 14% | 9% | 9% | 10% | 15% |
| Debtor days | 79 | 87 | 67 | 116 | 84 | 86 | 109 | 94 | 86 | 105 |
| Inventory days | 376 | 505 | 540 | 834 | 452 | 424 | 399 | 288 | 291 | 323 |
| Days payable | 84 | 100 | 93 | 261 | 204 | 101 | 141 | 98 | 122 | 110 |
| Cash conversion cycle | 371 | 491 | 514 | 690 | 332 | 409 | 367 | 284 | 255 | 318 |
| Working capital days | 90 | 82 | 106 | 104 | 134 | 113 | 88 | 112 | 74 | 54 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Hester Biosciences Ltd shareholding pattern
Promoters held 53.73% at Jun 2026, broadly unchanged since Jun 2025. FIIs 0.31% and DIIs 0.00%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 53.73% | 53.73% | 53.73% | 53.73% | 53.73% | 53.73% | 53.73% | 53.73% |
| FIIs | 0.61% | 0.59% | 0.87% | 0.51% | 0.53% | 0.52% | 0.38% | 0.31% |
| DIIs | 0.00% | 0.02% | 0.02% | 0.02% | 0.00% | 0.01% | 0.00% | 0.00% |
| Public | 45.66% | 45.65% | 45.38% | 45.73% | 45.73% | 45.75% | 45.88% | 45.95% |
| No. of shareholders | 11,538 | 11,473 | 11,853 | 11,810 | 12,260 | 12,603 | 12,373 | 11,961 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Hester Biosciences Ltd corporate filings
- Hester Biosciences Ltd discloses investment in LLP for group captive power generationCompany Updatelow impact
Cruxal's analysis: Hester Biosciences Ltd has filed a disclosure under SEBI Regulation 30 regarding an…
Read the full analysis - Hester Biosciences approves INR 10.50 million investment in Slyce Agri World LLP for renewable energy generationOthersmedium impact
Cruxal's analysis: Hester Biosciences Limited has announced a strategic investment of up to INR 10.50…
Read the full analysis - Closure of Trading WindowInsider Trading / SASTlow impact
- Hester Biosciences shareholders approve reclassification of Ravin and Bela Gandhi to public categoryCompany Updatelow impact
Cruxal's analysis: Hester Biosciences has received shareholder approval for the reclassification of Mr…
Read the full analysis - Hester Biosciences Limited shareholders approve reclassification of two promoters to public categoryAGM/EGMlow impact
Cruxal's analysis: Hester Biosciences Limited has successfully concluded a postal ballot process, with…
Read the full analysis - Hester Biosciences Limited Receives Credit Rating Upgrade from CARE Ratings to BBB+ StableCompany Updatemedium impact
Cruxal's analysis: Hester Biosciences Limited has received a credit rating upgrade from CARE Ratings, with…
Read the full analysis - Hester Biosciences Limited initiates promoter reclassification for Ravin Gandhi and Bela GandhiAGM/EGMlow impact
Cruxal's analysis: Hester Biosciences Limited has issued a postal ballot notice to seek shareholder approval…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.